ALIVUS Share Price Performance
₹933.80
-244.20 (-20.73%)
Price ₹933.80
Share Price₹933.80
Alivus Life Sciences Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
ALIVUS Community Narratives
There are no narratives available yet.
Recent ALIVUS News & Updates
Alivus Life Sciences Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 40.40
- Gross Margin
- 55.69%
- Net Profit Margin
- 20.65%
- Debt/Equity Ratio
- 2.0%
Alivus Life Sciences Limited Competitors
Snowflake Analysis
About ALIVUS
- Founded
- 2001
- Employees
- 2203
- CEO
- WebsiteView website
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Indian Market Performance
- 7 Days: 1.1%
- 3 Months: -0.1%
- 1 Year: -4.4%
- Year to Date: 1.3%
The market is up 1.1% over the last week, with the Information Technology sector leading the way, up 4.3%. In contrast, the market has seen a decline of 4.4% over the last 12 months. Earnings are forecast to grow by 16% annually. Market details ›